Last Updated: May 11, 2026

CLINICAL TRIALS PROFILE FOR DENILEUKIN DIFTITOX

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for denileukin diftitox

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006345 ↗	Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma	Completed	Ligand Pharmaceuticals	Phase 2	1999-11-01	RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox. PURPOSE: Phase II trial to study the effectiveness of dexamethasone in preventing side effects following treatment with denileukin diftitox in treating patients who have persistent or recurrent T-cell lymphoma.
NCT00023530 ↗	Blood and Marrow Transplant Clinical Research Network	Completed	Blood and Marrow Transplant Clinical Trials Network	N/A	2001-09-01	The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
NCT00023530 ↗	Blood and Marrow Transplant Clinical Research Network	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2001-09-01	The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
NCT00050999 ↗	Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients	Completed	Eisai Inc.	Phase 4	1995-06-01	The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for denileukin diftitox

Condition Name

Chart
Table

Condition Name for denileukin diftitox
Intervention	Trials
Epithelial Ovarian Cancer	3
Graft vs Host Disease	3
Lymphoma, T-Cell, Cutaneous	3
Lymphoma	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for denileukin diftitox
Intervention	Trials
Lymphoma	10
Lymphoma, T-Cell	7
Graft vs Host Disease	4
Carcinoma, Ovarian Epithelial	4
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for denileukin diftitox

Trials by Country

Map
Table

Trials by Country for denileukin diftitox
Location	Trials
United States	136
Canada	7
Australia	7
Brazil	4
Germany	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for denileukin diftitox
Location	Trials
Texas	14
New York	8
California	8
Pennsylvania	8
Missouri	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for denileukin diftitox

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for denileukin diftitox
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2	18
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for denileukin diftitox
Clinical Trial Phase	Trials
Completed	17
Terminated	6
Withdrawn	4
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for denileukin diftitox

Sponsor Name

Chart
Table

Sponsor Name for denileukin diftitox
Sponsor	Trials
Eisai Inc.	12
National Cancer Institute (NCI)	4
University of Louisville	3
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for denileukin diftitox
Sponsor	Trials
Other	36
Industry	16
NIH	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.